Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
出版年份 2022 全文链接
标题
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
作者
关键词
-
出版物
Biomolecules
Volume 12, Issue 6, Pages 784
出版商
MDPI AG
发表日期
2022-06-04
DOI
10.3390/biom12060784
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Design of smart nanomedicines for effective cancer treatment
- (2022) Niloofar Heshmati Aghda et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic
- (2022) Ana Isabel Fraguas-Sánchez et al. Cancers
- Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials
- (2022) Syed Nasir Abbas Bukhari Pharmaceutics
- Nanomaterials in cancer: Reviewing the combination of hyperthermia and triggered chemotherapy
- (2022) Tiago P. Ribeiro et al. JOURNAL OF CONTROLLED RELEASE
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
- (2021) Jaime Feliu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting metastatic cancer
- (2021) Karuna Ganesh et al. NATURE MEDICINE
- Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma
- (2021) Davendra P. S. Sohal et al. JAMA Oncology
- Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting
- (2021) Muhammad Abdur Rahim et al. Cancers
- A Concise Review: The Role of Stem Cells in Cancer Progression and Therapy
- (2021) Hasaan Hayat et al. OncoTargets and Therapy
- Nanoparticles for Targeted Drug Delivery to Cancer Stem Cells: A Review of Recent Advances
- (2021) Yavuz Nuri Ertas et al. Nanomaterials
- Magnetic-Guided Axillary UltraSound (MagUS) Sentinel Lymph Node Biopsy and Mapping in Patients with Early Breast Cancer. A Phase 2, Single-Arm Prospective Clinical Trial
- (2021) Allan Jazrawi et al. Cancers
- Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
- (2021) Julia C. F. Quintanilha et al. BRITISH JOURNAL OF CANCER
- Current treatment strategies and emerging therapies for cutaneous lymphoma
- (2021) Kentaro Yonekura JOURNAL OF DERMATOLOGY
- Nanoliposomes as drug delivery systems: safety concerns
- (2021) Yu. A. Tereshkina et al. JOURNAL OF DRUG TARGETING
- Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective
- (2021) Yongquan Tang et al. Pharmaceutics
- Enabling Technologies for Personalized and Precision Medicine
- (2020) Dean Ho et al. TRENDS IN BIOTECHNOLOGY
- Trastuzumab Deruxtecan: First Approval
- (2020) Susan J. Keam DRUGS
- Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches
- (2020) Harman Saman et al. Cancers
- Opportunities and challenges in commercial pharmaceutical liposome applications
- (2020) Gerard M. Jensen et al. ADVANCED DRUG DELIVERY REVIEWS
- Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
- (2020) James E. Frampton DRUGS
- A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407
- (2020) Luis Paz-Ares et al. Journal of Thoracic Oncology
- Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review
- (2020) Kevin Dzobo et al. Cells
- Protein-Based Nanoparticles as Drug Delivery Systems
- (2020) Seyoung Hong et al. Pharmaceutics
- Delivering the power of nanomedicine to patients today
- (2020) Matthieu Germain et al. JOURNAL OF CONTROLLED RELEASE
- Aspartate β-hydroxylase as a target for cancer therapy
- (2020) Madiha Kanwal et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- BCMA-targeted immunotherapy for multiple myeloma
- (2020) Bo Yu et al. Journal of Hematology & Oncology
- Recent advances in drug delivery systems for targeting cancer stem cells
- (2020) Hongxia Duan et al. Acta Pharmaceutica Sinica B
- Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization
- (2020) Vivek Makwana et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Engineering precision nanoparticles for drug delivery
- (2020) Michael J. Mitchell et al. NATURE REVIEWS DRUG DISCOVERY
- The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer
- (2020) Yi Shi et al. Frontiers in Pharmacology
- Antibody-Drug Conjugates (ADC) Against Cancer Stem-Like Cells (CSC)—Is There Still Room for Optimism?
- (2019) Fabrizio Marcucci et al. Frontiers in Oncology
- Polymers, responsiveness and cancer therapy
- (2019) Anil M. Pethe et al. Artificial Cells Nanomedicine and Biotechnology
- Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer
- (2019) Hanna K. Sanoff et al. Nanomedicine-Nanotechnology Biology and Medicine
- Targeting Tumor Microenvironment for Cancer Therapy
- (2019) Catarina Roma-Rodrigues et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
- (2019) Yasuhiro Fujiwara et al. BRITISH JOURNAL OF CANCER
- Impact on Health-Related Quality of Life of Induction Chemotherapy Compared With Concurrent Cisplatin and Radiation Therapy in Patients With Head and Neck Cancer
- (2019) D. Adkins et al. CLINICAL ONCOLOGY
- Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
- (2019) Young-A. Heo et al. DRUGS
- Markers of pancreatic cancer stem cells and their clinical and therapeutic implications
- (2019) Arkadiusz Gzil et al. MOLECULAR BIOLOGY REPORTS
- CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs)
- (2019) Tayoun et al. Cells
- The CXCL12-CXCR4 signaling axis plays a key role in cancer metastasis and is a potential target for developing novel therapeutics against metastatic cancer
- (2019) Ping Yang et al. CURRENT MEDICINAL CHEMISTRY
- Smart cancer nanomedicine
- (2019) Roy van der Meel et al. Nature Nanotechnology
- Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope
- (2019) Lucia Salvioni et al. Cancers
- Overcoming Physiological Barriers to Nanoparticle Delivery—Are We There Yet?
- (2019) Oliver S. Thomas et al. Frontiers in Bioengineering and Biotechnology
- nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
- (2018) D A Yardley et al. ANNALS OF ONCOLOGY
- ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies
- (2018) Francesca Zammarchi et al. BLOOD
- Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy’s history, efficacy and application in humans
- (2018) Keon Mahmoudi et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- Targeting the tumour stroma to improve cancer therapy
- (2018) Kenneth C. Valkenburg et al. Nature Reviews Clinical Oncology
- Cancer stem cells: regulation programs, immunological properties and immunotherapy
- (2018) Dingxiao Zhang et al. SEMINARS IN CANCER BIOLOGY
- Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
- (2018) Lan Thi Hanh Phi et al. Stem Cells International
- Selective depletion of metastatic stem cells as therapy for human colorectal cancer
- (2018) María Virtudes Céspedes et al. EMBO Molecular Medicine
- Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems
- (2018) Hassan Dianat-Moghadam et al. JOURNAL OF CONTROLLED RELEASE
- Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer
- (2018) Kristiaan J. Lenos et al. NATURE CELL BIOLOGY
- Porous Gold Nanoshells on Functional NH2 -MOFs: Facile Synthesis and Designable Platforms for Cancer Multiple Therapy
- (2018) Chuang Liu et al. Small
- Quantitative proteomic analysis to the first commercialized liposomal paclitaxel nano-platform Lipusu revealed the molecular mechanism of the enhanced anti-tumor effect
- (2018) Minzhi Zhao et al. Artificial Cells Nanomedicine and Biotechnology
- OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer
- (2018) T Y Seiwert et al. ANNALS OF ONCOLOGY
- The clinical role of the TME in solid cancer
- (2018) Nicolas A. Giraldo et al. BRITISH JOURNAL OF CANCER
- Nanomedicine in cancer stem cell therapy: from fringe to forefront
- (2018) Nazish Tabassum et al. CELL AND TISSUE RESEARCH
- Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy with Bevacizumab and Erlotinib
- (2018) L. Symonds et al. Clinical Breast Cancer
- Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities
- (2018) Fatemeh Farjadian et al. Nanomedicine
- Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
- (2017) Aleksandra Adamska et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
- (2017) Dimakatso Alice Senthebane et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Drug Resistance Driven by Cancer Stem Cells and Their Niche
- (2017) Marta Prieto-Vila et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Paclitaxel: What has been done and the challenges remain ahead
- (2017) Ezequiel Bernabeu et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Ontak-like human IL-2 fusion toxin
- (2017) Zhaohui Wang et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
- (2017) Ursula A. Germann et al. MOLECULAR CANCER THERAPEUTICS
- Cancer stem cells revisited
- (2017) Eduard Batlle et al. NATURE MEDICINE
- Tumour heterogeneity and resistance to cancer therapies
- (2017) Ibiayi Dagogo-Jack et al. Nature Reviews Clinical Oncology
- Targeting the Colorectal Cancer Stem Cell
- (2017) Jan Paul Medema NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Stem Cells (CSCs) as a Rational Therapeutic Cancer Target, and Screening for CSC-targeting Drugs
- (2017) Tetsuo Mashima YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
- Antibody fragments as nanoparticle targeting ligands: a step in the right direction
- (2017) Daniel A. Richards et al. Chemical Science
- Stem cells in cancer therapy: opportunities and challenges
- (2017) Cheng-Liang Zhang et al. Oncotarget
- Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases
- (2017) Lupe G. Salazar et al. JAMA Oncology
- Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735.
- (2017) D. W. Northfelt et al. JOURNAL OF CLINICAL ONCOLOGY
- Where Are the Nanodrugs? An Industry Perspective on Development of Drug Products Containing Nanomaterials
- (2016) Henry A. Havel AAPS Journal
- Cancer Stem Cells: Basic Concepts and Therapeutic Implications
- (2016) Dany Nassar et al. Annual Review of Pathology-Mechanisms of Disease
- SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
- (2016) Z. A. Nahleh et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck
- (2016) Stephen G. Chun et al. CANCER INVESTIGATION
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- Radiation Therapy Deviations in Trial of Locally Advanced Pancreatic Cancer
- (2016) Ashish Jani et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
- (2016) Aman P. Singh et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Endotoxin contamination: a key element in the interpretation of nanosafety studies
- (2016) Yang Li et al. Nanomedicine
- Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
- (2016) Daniel Bobo et al. PHARMACEUTICAL RESEARCH
- A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors
- (2016) Adam L. Cohen et al. Oncotarget
- Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma
- (2015) Lynn E. Spitler et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients
- (2015) Erin M. Bertino et al. Clinical Lung Cancer
- Assessment of the effects of sterilization methods on protein drug stability by elucidating decomposition mechanism and material analysis
- (2015) Koji Nakamura et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer
- (2015) P. E. Lammers et al. ONCOLOGIST
- Cancer nanomedicine: from targeted delivery to combination therapy
- (2015) Xiaoyang Xu et al. TRENDS IN MOLECULAR MEDICINE
- Albumin-bound paclitaxel in solid tumors: clinical development and future directions
- (2015) Madappa Kundranda et al. Drug Design Development and Therapy
- Magnetic Nanoparticles in Cancer Theranostics
- (2015) Oliviero L. Gobbo et al. Theranostics
- CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy
- (2015) Urszula M. Domanska et al. NEOPLASIA
- A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer
- (2014) Hee Kyung Ahn et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model
- (2014) Urszula M. Domanska et al. CLINICAL & EXPERIMENTAL METASTASIS
- Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer
- (2014) Ewa Mrózek et al. Clinical Breast Cancer
- nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer
- (2014) Vera Hirsh Expert Review of Anticancer Therapy
- Cancer active targeting by nanoparticles: a comprehensive review of literature
- (2014) Remon Bazak et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Stimuli-sensitive nanopreparations for combination cancer therapy
- (2014) Aditi Jhaveri et al. JOURNAL OF CONTROLLED RELEASE
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer
- (2014) R. M. Connolly et al. JOURNAL OF NUCLEAR MEDICINE
- Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects
- (2014) Sutapa Barua et al. Nano Today
- Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India
- (2013) A. A. Ranade et al. ANNALS OF ONCOLOGY
- Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer
- (2013) Joachim Rom et al. ANTI-CANCER DRUGS
- Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer
- (2013) Erika Hamilton et al. Clinical Breast Cancer
- Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
- (2013) Cheryl Ho et al. INVESTIGATIONAL NEW DRUGS
- The tumor microenvironment at a glance
- (2013) F. R. Balkwill et al. JOURNAL OF CELL SCIENCE
- nab-Paclitaxel mechanisms of action and delivery
- (2013) Denise A. Yardley JOURNAL OF CONTROLLED RELEASE
- The European Medicines Agency approval of 5-aminolaevulinic acid (Ameluz) for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
- (2013) Kyriaki Tzogani et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- How to escape the cancer attractor: Rationale and limitations of multi-target drugs
- (2013) Sui Huang et al. SEMINARS IN CANCER BIOLOGY
- Current Clinical Indications for Plerixafor
- (2013) Stefan Fruehauf TRANSFUSION MEDICINE AND HEMOTHERAPY
- Challenges in Development of Nanoparticle-Based Therapeutics
- (2012) Neil Desai AAPS Journal
- Targeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advances
- (2012) Shi Xu et al. ADVANCED DRUG DELIVERY REVIEWS
- Liposomal drug delivery systems: From concept to clinical applications
- (2012) Theresa M. Allen et al. ADVANCED DRUG DELIVERY REVIEWS
- A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
- (2012) Peter J. Hosein et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
- (2012) Denise A. Yardley et al. BREAST CANCER RESEARCH AND TREATMENT
- A randomized phase 2 study of temozolomide and bevacizumab ornab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma
- (2012) Lisa A. Kottschade et al. CANCER
- Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
- (2012) Jeffrey A. Silverman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study
- (2012) David S. Alberts et al. GYNECOLOGIC ONCOLOGY
- Cancer stem cells
- (2012) Zuoren Yu et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Doxil® — The first FDA-approved nano-drug: Lessons learned
- (2012) Yechezkel (Chezy) Barenholz JOURNAL OF CONTROLLED RELEASE
- A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer
- (2012) James M. Burke et al. JOURNAL OF UROLOGY
- Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
- (2012) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- Contamination of nanoparticles by endotoxin: evaluation of different test methods
- (2012) Stijn Smulders et al. Particle and Fibre Toxicology
- Molecular Imaging with Theranostic Nanoparticles
- (2011) Jesse V. Jokerst et al. ACCOUNTS OF CHEMICAL RESEARCH
- Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib
- (2011) Virginia G. Kaklamani et al. BREAST CANCER RESEARCH AND TREATMENT
- Receptor-Mediated Endocytosis of Nanoparticles of Various Shapes
- (2011) Robert Vácha et al. NANO LETTERS
- Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
- (2011) Larry Gold et al. PLoS One
- Discovery and Development of Therapeutic Aptamers
- (2010) P.R. Bouchard et al. Annual Review of Pharmacology and Toxicology
- A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer
- (2010) Denise Yardley et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma
- (2010) Lisa A. Kottschade et al. CANCER
- Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
- (2010) Alison K. Conlin et al. Clinical Breast Cancer
- Cancer nanotechnology: application of nanotechnology in cancer therapy
- (2010) Ranjita Misra et al. DRUG DISCOVERY TODAY
- Drug delivery and nanoparticles: Applications and hazards
- (2010) de Jong International Journal of Nanomedicine
- UV and Near-IR Triggered Release from Polymeric Nanoparticles
- (2010) Nadezda Fomina et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Targeting cancer stem cells by inhibiting Wnt, Notch and Hedgehog pathways
- (2010) Naoko Takebe et al. Nature Reviews Clinical Oncology
- Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds
- (2010) Pilar Rivera Gil et al. PHARMACOLOGICAL RESEARCH
- Review of mifamurtide in the treatment of patients with osteosarcoma
- (2010) Leo Kager et al. Therapeutics and Clinical Risk Management
- Effects of nanomaterial physicochemical properties on in vivo toxicity
- (2009) Kristin L. Aillon et al. ADVANCED DRUG DELIVERY REVIEWS
- Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
- (2009) D. Dornan et al. BLOOD
- Phase II Evaluation of Nanoparticle Albumin–Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
- (2009) Michael G. Teneriello et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding biophysicochemical interactions at the nano–bio interface
- (2009) Andre E. Nel et al. NATURE MATERIALS
- Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide
- (2008) E. J. Ip et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane(R)) in combination with gemcitabine in patients with metastatic breast cancer (N0531)
- (2008) V. Roy et al. ANNALS OF ONCOLOGY
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Therapeutic Nanoparticles for Drug Delivery in Cancer
- (2008) K. Cho et al. CLINICAL CANCER RESEARCH
- Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
- (2008) Vladimir Torchilin EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation